The research project, APRINHA, is being carried out by JPIAMR (the Joint Programming Initiative on Antimicrobial Resistance). It will explore the strong potential of inhaled antibiotics to help reduce antibiotic resistance - an urgent issue for researchers as antibiotic resistance has surged during the COVID-19 pandemic due to a dramatic increase in the use of antibiotics to treat pulmonary complications, co-infections and secondary infections.

The first proposal that ISAB and RISE submitted, as part of a wider consortium, has been invited to proceed to the next level. It received encouraging feedback from JPIAMR's scientific review panel: "The project is well-written; the consortium has all the expertise to achieve the goals of the project... one of the strengths of the project is that it has potential for other multiresistant bacteria, with approaches that can be translated for other infectious models."

The consortium must now submit a full proposal by July 5. ISAB's pre-clinical in vivo technology will play an important role. Its unique one-animal-at-a-time technology enables the individual control of inhaled doses of aerosol and delivers high-precisians results with a standard deviation of <10%.

Ian Cotgreave, Vice President of the Department for Chemical and Pharmaceutical Safety, RISE: "We have had very positive experience with PreciseInhale, our ISAB aerosol system, and we welcome the expertise in aerosol delivery and PK studies that the ISAB team will combine with ours as we move forward."

Manoush Masarrat, CEO ISAB: "This is an international project with applications from top research organizations and consortia worldwide. We are very pleased to be partnering together with RISE, an important partner in inhalation drug development, at this level."